Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord-derived mesenchymal stem cells (Tianjin Amcellgene Engineering)
- Development stage
- Unknown
- Lead developer
- Tianjin Angsai Cell Gene Engineering
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) developed by Tianjin AmCellGene Engineering is an off-the-shelf, GMP-grade cell therapy product. The therapy consists of cryopreserved third-party UC-MSCs formulated with DMSO and human serum albumin, requiring thawing prior to administration. It functions through mesenchymal stem cell-mediated immunomodulation, anti-inflammation, and tissue repair/regeneration. The China National Medical Products Administration (NMPA) has approved clinical trials for this product across several indications, including graft-versus-host disease (GVHD), acute-on-chronic liver failure (ACLF), acute ischemic stroke, refractory immune thrombocytopenia (ITP), and severe aplastic anemia. The product is currently being evaluated in Phase I and Phase II clinical trials.
- Other names
- 注射用间充质干细胞（脐带）Injectable Mesenchymal Stem Cells (Umbilical Cord)allogeneic umbilical cord-derived mesenchymal stem cellsUC-MSCs (AmCellGene)
Beyond the preview
Go deeper on allogeneic umbilical cord-derived mesenchymal stem cells (Tianjin Amcellgene Engineering).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord-derived mesenchymal stem cells (Tianjin Amcellgene Engineering).